# Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases

> **NCT01442935** · PHASE2 · COMPLETED · sponsor: **UNICANCER** · enrollment: 256 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Folinic Acid
- **DRUG:** 5-FU
- **DRUG:** Irinotecan
- **DRUG:** Irinotecan
- **DRUG:** Bevacizumab
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT01442935
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2015-12
- **Final completion:** 2021-01
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2021-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01442935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01442935, "Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01442935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*